{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T15:56:50Z","timestamp":1792166210515,"version":"4.4.0"},"reference-count":45,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,11]]},"abstract":"<jats:p>Colchicine, an established anti-inflammatory drug, is examined for its potential in mitigating adverse cardiovascular events following acute coronary syndrome (ACS). ACS, primarily triggered by plaque rupture and subsequent thrombosis, is a critical cardiovascular condition. Colchicine\u2019s mechanism of action involves inhibiting microtubule activity, leading to immobilization of white blood cells and reducing inflammation. Clinical data from studies, including low-dose colchicine for secondary prevention of cardiovascular disease two and colchicine cardiovascular outcomes trial, support its efficacy in reducing major cardiovascular events post-ACS, though some studies report varying results. Colchicine can cause transient gastrointestinal side effects and is prescribed with caution in patients with certain medical conditions. The recent FDA approval of a low dose of colchicine reiterates its benefit in reducing cardiovascular risk. The cost-effectiveness of colchicine products (0.5 and 0.6\u2009mg doses) are compared, suggesting the generic 0.6\u2009mg dose of colchicine to be an alternative to branded forms of the drug.<\/jats:p>","DOI":"10.1097\/crd.0000000000000650","type":"journal-article","created":{"date-parts":[[2024,1,8]],"date-time":"2024-01-08T09:01:00Z","timestamp":1704704460000},"page":"517-521","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":3,"title":["Low-Dose Colchicine for the Prevention of Cardiovascular Events After Acute Coronary Syndrome"],"prefix":"10.1097","volume":"33","author":[{"given":"Priyanka","family":"Gera","sequence":"first","affiliation":[{"name":"From the Westchester Medical Center, New York Medical College, Valhalla, NY."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David Haner","family":"Wasserstein","sequence":"additional","affiliation":[{"name":"From the Westchester Medical Center, New York Medical College, Valhalla, NY."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William H.","family":"Frishman","sequence":"additional","affiliation":[{"name":"From the Westchester Medical Center, New York Medical College, Valhalla, NY."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wilbert S.","family":"Aronow","sequence":"additional","affiliation":[{"name":"From the Westchester Medical Center, New York Medical College, Valhalla, NY."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2024,1,8]]},"reference":[{"key":"R1-20251003","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1097\/CRD.0000000000000021","article-title":"Inflammation and atherosclerosis: a review of the role of interleukin-6 in the development of atherosclerosis and the potential for targeted drug therapy.","volume":"22","author":"Hartman","year":"2014","journal-title":"Cardiol Rev"},{"key":"R2-20251003","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1056\/NEJM199901143400207","article-title":"Atherosclerosis--an inflammatory disease.","volume":"340","author":"Ross","year":"1999","journal-title":"N Engl J Med"},{"key":"R3-20251003","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1097\/CRD.0000000000000062","article-title":"Therapeutic role of innovative anti-inflammatory medications in the prevention of acute coronary syndrome.","volume":"23","author":"Pashun","year":"2015","journal-title":"Cardiol Rev"},{"key":"R4-20251003","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1097\/00001573-200109000-00006","article-title":"The thin-cap fibroatheroma: a type of vulnerable plaque: the major precursor lesion to acute coronary syndromes.","volume":"16","author":"Kolodgie","year":"2001","journal-title":"Curr Opin Cardiol"},{"key":"R5-20251003","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1038\/s41586-021-03392-8","article-title":"The changing landscape of atherosclerosis.","volume":"592","author":"Libby","year":"2021","journal-title":"Nature"},{"key":"R6-20251003","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.ejim.2021.10.002","article-title":"Colchicine - new horizons for an ancient drug review based on the highest hierarchy of evidence.","volume":"96","author":"Schattner","year":"2022","journal-title":"Eur J Intern Med"},{"key":"R7-20251003","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1161\/CIRCULATIONAHA.121.056171","article-title":"Colchicine in cardiovascular disease: in-depth review.","volume":"145","author":"Deftereos","year":"2022","journal-title":"Circulation"},{"key":"R8-20251003","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1007\/s11845-022-02938-7","article-title":"Colchicine-regeneration of an old drug.","volume":"192","author":"Casey","year":"2023","journal-title":"Ir J Med Sci"},{"key":"R9-20251003","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1002\/cbin.10988","article-title":"Colchicine, a microtubule-disassembling drug, in the therapy of cardiovascular diseases.","volume":"42","author":"Chaldakov","year":"2018","journal-title":"Cell Biol Int"},{"key":"R10-20251003","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/j.amjmed.2021.01.019","article-title":"The use of colchicine in cardiovascular diseases: a systematic review.","volume":"134","author":"Siak","year":"2021","journal-title":"Am J Med"},{"key":"R12-20251003","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/j.atherosclerosis.2017.12.027","article-title":"The NLRP3 inflammasome and the emerging role of colchicine to inhibit atherosclerosis-associated inflammation.","volume":"269","author":"Mart\u00ednez","year":"2018","journal-title":"Atherosclerosis"},{"key":"R13-20251003","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1172\/JCI118147","article-title":"Colchicine alters the quantitative and qualitative display of selectins on endothelial cells and neutrophils.","volume":"96","author":"Cronstein","year":"1995","journal-title":"J Clin Invest"},{"key":"R14-20251003","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1084\/jem.171.3.715","article-title":"Downregulation of tumor necrosis factor receptors on macrophages and endothelial cells by microtubule depolymerizing agents.","volume":"171","author":"Ding","year":"1990","journal-title":"J Exp Med"},{"key":"R15-20251003","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.amjmed.2021.07.025","article-title":"Consensus statement regarding the efficacy and safety of long-term low-dose colchicine in gout and cardiovascular disease.","volume":"135","author":"Robinson","year":"2022","journal-title":"Am J Med"},{"key":"R17-20251003","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1007\/s40261-022-01209-8","article-title":"The effect of years-long exposure to low-dose colchicine on renal and liver function and blood creatine kinase levels: safety insights from the low-dose colchicine 2 (LoDoCo2) trial.","volume":"42","author":"van Broekhoven","year":"2022","journal-title":"Clin Drug Investig"},{"key":"R18-20251003","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1007\/s11739-021-02654-7","article-title":"Colchicine efficacy and safety for the treatment of cardiovascular diseases.","volume":"16","author":"Andreis","year":"2021","journal-title":"Intern Emerg Med"},{"key":"R19-20251003","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1007\/s11926-002-0073-2","article-title":"Update on colchicine and its mechanism of action.","volume":"4","author":"Molad","year":"2002","journal-title":"Curr Rheumatol Rep"},{"key":"R20-20251003","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1172\/JCI109855","article-title":"Platelets and microtubules effect of colchicine and D2O on platelet aggregation and release induced by calcium ionophore A23187.","volume":"66","author":"Menche","year":"1980","journal-title":"J Clin Invest"},{"key":"R21-20251003","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1186\/s12872-021-02393-9","article-title":"Effects of colchicine on major adverse cardiac events in next 6-month period after acute coronary syndrome occurrence; a randomized placebo-control trial.","volume":"21","author":"Akrami","year":"2021","journal-title":"BMC Cardiovasc Disord"},{"key":"R22-20251003","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1007\/s11239-011-0637-y","article-title":"Effect of colchicine compared with placebo on high sensitivity C-reactive protein in patients with acute coronary syndrome or acute stroke: a pilot randomized controlled trial.","volume":"33","author":"Raju","year":"2012","journal-title":"J Thromb Thrombolysis"},{"key":"R23-20251003","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1161\/CIRCULATIONAHA.115.017611","article-title":"Anti-inflammatory treatment with colchicine in acute myocardial infarction.","volume":"132","author":"Deftereos","year":"2015","journal-title":"Circulation"},{"key":"R24-20251003","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.ijcard.2019.01.054","article-title":"Effect of short-term colchicine treatment on endothelial function in patients with coronary artery disease.","volume":"281","author":"Kajikawa","year":"2019","journal-title":"Int J Cardiol"},{"key":"R25-20251003","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.jcmg.2017.08.013","article-title":"Colchicine therapy and plaque stabilization in patients with acute coronary syndrome: a CT coronary angiography study.","volume":"11","author":"Vaidya","year":"2018","journal-title":"JACC Cardiovasc Imaging"},{"key":"R26-20251003","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.1056\/NEJMoa2021372","article-title":"Colchicine in patients with chronic coronary disease.","volume":"383","author":"Nidorf","year":"2020","journal-title":"N Engl J Med"},{"key":"R27-20251003","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1056\/NEJMoa1912388","article-title":"Efficacy and safety of low-dose colchicine after myocardial infarction.","volume":"381","author":"Tardif","year":"2019","journal-title":"N Engl J Med"},{"key":"R28-20251003","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/j.jacc.2012.10.027","article-title":"Low-dose colchicine for secondary prevention of cardiovascular disease.","volume":"61","author":"Nidorf","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"R29-20251003","doi-asserted-by":"crossref","first-page":"1890","DOI":"10.1161\/CIRCULATIONAHA.120.050771","article-title":"Colchicine in patients with acute coronary syndrome: the australian COPS randomized clinical trial.","volume":"142","author":"Tong","year":"2020","journal-title":"Circulation"},{"key":"R30-20251003","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.acvd.2016.10.004","article-title":"COLIN trial: Value of colchicine in the treatment of patients with acute myocardial infarction and inflammatory response.","volume":"110","author":"Akodad","year":"2017","journal-title":"Arch Cardiovasc Dis"},{"key":"R31-20251003","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1097\/FJC.0000000000001317","article-title":"Preprocedural colchicine in patients with acute ST-elevation myocardial infarction undergoing percutaneous coronary intervention: a randomized controlled trial (PodCAST-PCI).","volume":"80","author":"Hosseini","year":"2022","journal-title":"J Cardiovasc Pharmacol"},{"key":"R32-20251003","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.ahj.2019.06.003","article-title":"The low dose colchicine after myocardial infarction (LoDoCo-MI) study: a pilot randomized placebo controlled trial of colchicine following acute myocardial infarction.","volume":"215","author":"Hennessy","year":"2019","journal-title":"Am Heart J"},{"key":"R33-20251003","doi-asserted-by":"crossref","first-page":"e008717","DOI":"10.1161\/CIRCINTERVENTIONS.119.008717","article-title":"Effects of acute colchicine administration prior to percutaneous coronary intervention.","volume":"13","author":"Shah","year":"2020","journal-title":"Circ Cardiovasc Interv"},{"key":"R34-20251003","doi-asserted-by":"crossref","first-page":"8317011","DOI":"10.1155\/2022\/8317011","article-title":"Effect of treatment with colchicine after acute coronary syndrome on major cardiovascular events: a systematic review and meta-analysis of clinical trials.","volume":"2022","author":"Razavi","year":"2022","journal-title":"Cardiovasc Ther"},{"key":"R35-20251003","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1016\/S0735-1097(22)02014-9","article-title":"The anti-inflammatory world of colchicine: utilization, cost and insight into coronary artery disease indications.","volume":"79","author":"Abraham","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"R36-20251003","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1185\/03007995.2011.563284","article-title":"A new perspective on the pharmacoeconomics of colchicine.","volume":"27","author":"Wertheimer","year":"2011","journal-title":"Curr Med Res Opin"},{"key":"R37-20251003","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1007\/s11606-015-3285-7","article-title":"Reductions in use of colchicine after FDA enforcement of market exclusivity in a commercially insured population.","volume":"30","author":"Kesselheim","year":"2015","journal-title":"J Gen Intern Med"},{"key":"R38-20251003","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1093\/ehjqcco\/qcx043","article-title":"Cost-effectiveness of colchicine treatment on post-operative atrial fibrillation events in patients of major cardiac surgery.","volume":"4","author":"Barman","year":"2018","journal-title":"Eur Heart J Qual Care Clin Outcomes"},{"key":"R39-20251003","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1016\/j.cjco.2023.02.005","article-title":"Cost-Effectiveness of colchicine for recurrent cardiovascular events.","volume":"5","author":"Boczar","year":"2023","journal-title":"CJC Open"},{"key":"R40-20251003","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1093\/ehjqcco\/qcaa045","article-title":"Cost-effectiveness of low-dose colchicine after myocardial infarction in the Colchicine Cardiovascular Outcomes Trial (COLCOT).","volume":"7","author":"Samuel","year":"2021","journal-title":"Eur Heart J Qual Care Clin Outcomes"},{"key":"R41-20251003","first-page":"1837","article-title":"Colchicine for prevention of atherothrombotic events in patients with coronary artery disease: review and practical approach for clinicians.","volume":"37","author":"Marquis-Gravel","year":"2021","journal-title":"Can J Cardiol"},{"key":"R42-20251003","first-page":"e1","article-title":"Colchicine may decrease cardiovascular events in patients with coronary artery disease.","volume":"71","author":"Griffin","year":"2022","journal-title":"J Fam Pract"},{"key":"R43-20251003","doi-asserted-by":"crossref","first-page":"156","DOI":"10.58347\/tml.2023.1686b","article-title":"Lodoco: Low-Dose Colchicine for Cardiovascular Event Prevention.","volume":"65","year":"2023","journal-title":"Med Lett Drugs Ther"},{"key":"R44-20251003","doi-asserted-by":"crossref","first-page":"156","DOI":"10.58347\/tml.2023.1686b","volume":"65","year":"2023","journal-title":"Med Lett Drugs Ther"},{"key":"R45-20251003","doi-asserted-by":"crossref","first-page":"637","DOI":"10.2459\/JCM.0000000000001157","article-title":"Adverse events of colchicine for cardiovascular diseases: a comprehensive meta-analysis of 14 188 patients from 21 randomized controlled trials.","volume":"22","author":"Andreis","year":"2021","journal-title":"J Cardiovasc Med (Hagerstown)"},{"key":"R46-20251003","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1016\/j.jcin.2023.05.035","article-title":"P2Y12 inhibitor monotherapy combined with colchicine following PCI in ACS patients: the MACT pilot study.","volume":"16","author":"Lee","year":"2023","journal-title":"JACC Cardiovasc Interv"},{"key":"R47-20251003","doi-asserted-by":"crossref","first-page":"52","DOI":"10.2459\/JCM.0000000000001389","article-title":"Rationale and design of COLchicine On-admission to Reduce inflammation in Acute Coronary Syndrome (COLOR-ACS) study.","volume":"24","author":"Toso","year":"2023","journal-title":"J Cardiovasc Med (Hagerstown)"}],"container-title":["Cardiology in Review"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/CRD.0000000000000650","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T00:00:13Z","timestamp":1759536013000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/CRD.0000000000000650"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,8]]},"references-count":45,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/crd.0000000000000650","relation":{},"ISSN":["1538-4683"],"issn-type":[{"value":"1538-4683","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,8]]}}}